Effects of Intranasal Oxytocin and Stress on Belief Updating

NCT03597893 | Completed

• 1 other identifier: OB-OT and stress
• Study Type: interventional
• Target: 131
• Locations: 0 countries
• Sites: N/A

Brief Summary

To investigate the effect of 24IU intranasal oxytocin on belief updating when people in stress or non-stress condition.

Conditions

Healthy

Keywords

intranasal oxytocin; stress; belief updating

Outcome Measures

Primary Outcomes (3)

• The updated probability estimation for negative events in the four experimental groups

  Using the second estimation value to minus the first estimation value to get the update value, as well as calculating the update value in desirable condition (first estimation \< feedback) and undesirable condition (first estimation \< feedback). Then investigated the general belief updating (gBU) and optimistic belief updating (using desirableBU-undesirableBU) in the four experimental condition (i.e., oxytocin-stress, oxytocin-nonstress, placebo-stress, placebo-nonstress).

  40~125 minutes after drug administration

• The salivary cortisol level in four experimental groups

  Conducted ANOVA to test salivary cortisol level in the four experimental groups

  40~125 minutes after drug administration

• The correlation between personality traits and belief updating value in four experimental groups

  Conducted correlation analysis to explore which personality traits would modulate the oxytocin effect or stress effect.

  40~125 minutes after drug administration

Study Arms (2)

Oxytocin

EXPERIMENTAL

Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .

Drug: Oxytocin

Placebo

PLACEBO COMPARATOR

Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.

Drug: Placebo

Interventions

Oxytocin DRUG

intranasally administrated

Oxytocin

Placebo DRUG

intranasally administrated

Also known as: Saline

Placebo

Eligibility Criteria

• Age: 18 Years - 40 Years
• Gender Eligibility Details: we opted to recruit only males for the present study.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• healthy subjects without past or current psychiatric or neurological disorders

You may not qualify if:

• subjects with past or current psychiatric or neurological disorders

Sponsors & Collaborators

• Beijing Normal University: lead

MeSH Terms

Interventions

Oxytocin; Sodium Chloride

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: The study utilized a randomized, double-blind, PBO controlled, between-subject design.

Study Record Dates

• First Submitted: July 2, 2018
• First Posted: July 24, 2018
• Study Start: December 27, 2016
• Primary Completion: August 15, 2017
• Study Completion: June 30, 2018
• Last Updated: July 24, 2018

Record last verified: 2018-07